We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · July 22, 2021

SBRT Plus Pembrolizumab and Trametinib vs SBRT Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Stereotactic Body Radiotherapy Plus Pembrolizumab and Trametinib Versus Stereotactic Body Radiotherapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: An Open-Label, Randomised, Controlled, Phase 2 Trial
Lancet Oncol 2021 Jul 05;[EPub Ahead of Print], X Zhu, Y Cao, W Liu, X Ju, X Zhao, L Jiang, Y Ye, G Jin, H Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading